We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

RCT on Adjuvant TACE After Hepatectomy for HCC (A-TECH)

This study is currently recruiting participants.
Verified February 2015 by Cheung Yue Sun, Chinese University of Hong Kong
Sponsor:
ClinicalTrials.gov Identifier:
NCT01512407
First Posted: January 19, 2012
Last Update Posted: February 4, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cheung Yue Sun, Chinese University of Hong Kong
  Purpose
We hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival. The aim of this study is to compare the survival of patients undergoing liver resection plus post-operative TACE versus liver resection alone.

Condition Intervention Phase
Hepatocellular Carcinoma Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by Cheung Yue Sun, Chinese University of Hong Kong:

Primary Outcome Measures:
  • 1-year recurrence rate [ Time Frame: 1-year after hepatectomy ]
    The 1-year recurrence rate after hepatectomy in both arms of study were compared


Secondary Outcome Measures:
  • Disease-free survival [ Time Frame: 5 years after operation ]
  • Overall Survival [ Time Frame: 5-year after surgery ]
  • Complications of transarterial chemoembolisation [ Time Frame: 3-month after transarterial chemoembolisation ]
  • Health-related quality of life assessment [ Time Frame: 1-year after surgery ]
    The quality of life assessment was measured by Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire (Chinese version 3)


Estimated Enrollment: 144
Study Start Date: January 2012
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hepatectomy plus TACE
Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture
Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
No Intervention: Hepatectomy alone

Detailed Description:
Liver resection is the mainstay of curative treatment for hepatocellular carcinoma (HCC). However, recurrence is common after surgery and most occurs in the liver. Transarterial chemoembolisation (TACE) is an effective palliative treatment for HCC. It involves the infusion of chemotherapeutic agent admixed with iodised oil followed by embolisation of the hepatic arterial flow using small particles. This procedures allows application of smaller dose of chemotherapy concentrated to the liver and thus is well tolerated with minimal side effects. We conduct a randomised controlled trial evaluating the efficacy of using TACE after hepatectomy in HCC patients.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HCC patients received curative hepatectomy with negative resection margin
  • Age from 18 to 70
  • Child-Pugh class A
  • ASA class I to III
  • ECOG performance status Grade 0 or 1

Exclusion Criteria:

  • Patients receiving concomitant local ablation or previous TACE
  • Main portal vein tumour thrombus extraction during hepatectomy
  • Tumour arising from caudate lobe
  • Presence of extra-hepatic disease
  • Very early HCC with solitary tumour and size < 2cm
  • Impaired liver function with either clinically detected ascites, hepatic encephalopathy, serum albumin < 25g/L or bilirubin > 50micromol/L
  • Renal impairment with creatinine > 200micromol/L
  • Severe concurrent medical illness persisting > 6 weeks after hepatectomy
  • History of other cancer
  • Hepatic artery anomaly making TACE not possible
  • Allergy to cisplatin or lipiodol
  • Pregnant woman
  • Informed consent not available
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01512407


Contacts
Contact: Yue Sun Cheung, MBChB (852) 26321411 yuesun@surgery.cuhk.edu.hk

Locations
China
Prince of Wales Hospital Recruiting
Hong Kong, China
Contact: Yue Sun Cheung, MBChB    (852) 26321411    yuesun@surgery.cuhk.edu.hk   
Principal Investigator: Yue Sun Cheung, MBChB         
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Principal Investigator: Yue Sun Cheung, MBChB Chinese University of Hong Kong
  More Information

Responsible Party: Cheung Yue Sun, Dr Cheung Yue Sun, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT01512407     History of Changes
Other Study ID Numbers: CRE-2011.236-T
First Submitted: January 14, 2012
First Posted: January 19, 2012
Last Update Posted: February 4, 2015
Last Verified: February 2015

Keywords provided by Cheung Yue Sun, Chinese University of Hong Kong:
Hepatocellular Carcinoma
Randomised controlled trial
Transarterial chemoembolisation

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Cisplatin
Ethiodized Oil
Antineoplastic Agents